Ioannis Tomazos

Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria

John Devin Peipert, Austin Kulasekararaj, Anna Gayà et al. · PLoS ONE · 2020 · 48 citations · Full text

Medicine, Hematology, Pharmacotherapy +13

Comparative efficacy of ravulizumab and eculizumab in the treatment of atypical hemolytic uremic syndrome: An indirect comparison using clinical trial data

Ioannis Tomazos, Anthony J. Hatswell, Spero Cataland et al. · Clinical Nephrology · 2021 · 36 citations · Full text

Pharmacy, Hematology, Pharmacotherapy +14

A US cost-minimization model comparing ravulizumab versus eculizumab for the treatment of atypical hemolytic uremic syndrome

Yan Wang, Karissa Johnston, Evan Popoff et al. · Journal of Medical Economics · 2020 · 33 citations

Pharmacy, Pharmacoeconomics, Pharmacotherapy +17

Clinically important change for the FACIT-Fatigue scale in paroxysmal nocturnal hemoglobinuria: a derivation from international PNH registry patient data

David Cella, Peter Johansson, Yasutaka Ueda et al. · Journal of Patient-Reported Outcomes · 2023 · 27 citations · Full text

Medicine, Hematology, Pharmacotherapy +12

Cost-Utility Analysis of Ravulizumab Compared with Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria

Thomas O’Connell, Marric Buessing, Scott J. Johnson et al. · PharmacoEconomics · 2020 · 24 citations · Full text

Pharmacy, Hematology, Pharmacotherapy +17